Literature DB >> 25363656

Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability.

Katrine B V Greve1, Jonas N Lindgreen1, Mikkel G Terp2, Christina B Pedersen1, Steffen Schmidt2, Jan Mollenhauer2, Stine B Kristensen1, Rikke S Andersen1, Mette M Relster1, Henrik J Ditzel3, Morten F Gjerstorff4.   

Abstract

SSX cancer/testis antigens are frequently expressed in melanoma tumors and represent attractive targets for immunotherapy, but their role in melanoma tumorigenesis has remained elusive. Here, we investigated the cellular effects of SSX2 expression. In A375 melanoma cells, SSX2 expression resulted in an increased DNA content and enlargement of cell nuclei, suggestive of replication aberrations. The cells further displayed signs of DNA damage and genomic instability, associated with p53-mediated G1 cell cycle arrest and a late apoptotic response. These results suggest a model wherein SSX2-mediated replication stress translates into mitotic defects and genomic instability. Arrest of cell growth and induction of DNA double-strand breaks was also observed in MCF7 breast cancer cells in response to SSX2 expression. Additionally, MCF7 cells with ectopic SSX2 expression demonstrated typical signs of senescence (i.e. an irregular and enlarged cell shape, enhanced β-galactosidase activity and DNA double-strand breaks). Since replication defects, DNA damage and senescence are interconnected and well-documented effects of oncogene expression, we tested the oncogenic potential of SSX2. Importantly, knockdown of SSX2 expression in melanoma cell lines demonstrated that SSX2 supports the growth of melanoma cells. Our results reveal two important phenotypes of ectopic SSX2 expression that may drive/support tumorigenesis: First, immediate induction of genomic instability, and second, long-term support of tumor cell growth.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer/testis antigen; Genomic instability; Oncogene; SSX2; Senescence

Mesh:

Substances:

Year:  2014        PMID: 25363656      PMCID: PMC5528659          DOI: 10.1016/j.molonc.2014.09.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  32 in total

1.  Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies.

Authors:  U Sahin; O Türeci; Y T Chen; G Seitz; C Villena-Heinsen; L J Old; M Pfreundschuh
Journal:  Int J Cancer       Date:  1998-10-29       Impact factor: 7.396

2.  Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma.

Authors:  A J Zendman; N J de Wit; A A van Kraats; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Melanoma Res       Date:  2001-10       Impact factor: 3.599

Review 3.  Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.

Authors:  Morten Frier Gjerstorff; Jorge Burns; Henrik Jorn Ditzel
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

4.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints.

Authors:  Jirina Bartkova; Nousin Rezaei; Michalis Liontos; Panagiotis Karakaidos; Dimitris Kletsas; Natalia Issaeva; Leandros-Vassilios F Vassiliou; Evangelos Kolettas; Katerina Niforou; Vassilis C Zoumpourlis; Munenori Takaoka; Hiroshi Nakagawa; Frederic Tort; Kasper Fugger; Fredrik Johansson; Maxwell Sehested; Claus L Andersen; Lars Dyrskjot; Torben Ørntoft; Jiri Lukas; Christos Kittas; Thomas Helleday; Thanos D Halazonetis; Jiri Bartek; Vassilis G Gorgoulis
Journal:  Nature       Date:  2006-11-30       Impact factor: 49.962

5.  Cytometric assessment of histone H2AX phosphorylation: a reporter of DNA damage.

Authors:  Xuan Huang; Zbigniew Darzynkiewicz
Journal:  Methods Mol Biol       Date:  2006

6.  Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint.

Authors:  Wenge Zhu; Yuefeng Chen; Anindya Dutta
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

7.  Tumor antigen expression in melanoma varies according to antigen and stage.

Authors:  Catherine Barrow; Judy Browning; Duncan MacGregor; Ian D Davis; Sue Sturrock; Achim A Jungbluth; Jonathan Cebon
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

Review 8.  An oncogene-induced DNA damage model for cancer development.

Authors:  Thanos D Halazonetis; Vassilis G Gorgoulis; Jiri Bartek
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728

9.  SSX2-4 expression in early-stage non-small cell lung cancer.

Authors:  K B V Greve; M Pøhl; K E Olsen; O Nielsen; H J Ditzel; M F Gjerstorff
Journal:  Tissue Antigens       Date:  2014-03-20

10.  The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.

Authors:  Roy Barco; Christina B Garcia; Josiane E Eid
Journal:  PLoS One       Date:  2009-04-01       Impact factor: 3.240

View more
  18 in total

1.  Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability.

Authors:  Katrine B V Greve; Jonas N Lindgreen; Mikkel G Terp; Christina B Pedersen; Steffen Schmidt; Jan Mollenhauer; Stine B Kristensen; Rikke S Andersen; Mette M Relster; Henrik J Ditzel; Morten F Gjerstorff
Journal:  Mol Oncol       Date:  2014-10-06       Impact factor: 6.603

Review 2.  Cancer Immunoprevention: Current Status and Future Directions.

Authors:  Mahsa Keshavarz-Fathi; Nima Rezaei
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-02-27       Impact factor: 4.291

3.  Long-term expression changes of immune-related genes in prostate cancer after radiotherapy.

Authors:  Iris Eke; Molykutty J Aryankalayil; Michelle A Bylicky; Veit Sandfort; Claire Vanpouille-Box; Saravanan Nandagopal; Edward E Graves; Amato J Giaccia; C Norman Coleman
Journal:  Cancer Immunol Immunother       Date:  2021-08-25       Impact factor: 6.968

4.  Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.

Authors:  Valentina Hoyos; Spyridoula Vasileiou; Manik Kuvalekar; Ayumi Watanabe; Ifigeneia Tzannou; Yovana Velazquez; Matthew French-Kim; Wingchi Leung; Suhasini Lulla; Catherine Robertson; Claudette Foreman; Tao Wang; Shaun Bulsara; Natalia Lapteva; Bambi Grilley; Matthew Ellis; Charles Kent Osborne; Angela Coscio; Julie Nangia; Helen E Heslop; Cliona M Rooney; Juan F Vera; Premal Lulla; Mothaffar Rimawi; Ann M Leen
Journal:  Ther Adv Med Oncol       Date:  2022-07-15       Impact factor: 5.485

Review 5.  Tools used to assay genomic instability in cancers and cancer meiomitosis.

Authors:  Jennifer Gantchev; Brandon Ramchatesingh; Melissa Berman-Rosa; Daniel Sikorski; Keerthenan Raveendra; Laetitia Amar; Hong Hao Xu; Amelia Martínez Villarreal; Daniel Josue Guerra Ordaz; Ivan V Litvinov
Journal:  J Cell Commun Signal       Date:  2021-11-29       Impact factor: 5.908

6.  The ectopic expression of meiCT genes promotes meiomitosis and may facilitate carcinogenesis.

Authors:  Jennifer Gantchev; Amelia Martínez Villarreal; Scott Gunn; Monique Zetka; Neils Ødum; Ivan V Litvinov
Journal:  Cell Cycle       Date:  2020-03-30       Impact factor: 4.534

7.  Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins.

Authors:  Wen Jian; Xin Li; Jian Kang; Yingfeng Lei; Yinlan Bai; Ying Xue
Journal:  Exp Ther Med       Date:  2018-07-09       Impact factor: 2.447

Review 8.  Oncogenic cancer/testis antigens: prime candidates for immunotherapy.

Authors:  Morten F Gjerstorff; Mads H Andersen; Henrik J Ditzel
Journal:  Oncotarget       Date:  2015-06-30

Review 9.  Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability.

Authors:  Aaraby Yoheswaran Nielsen; Morten Frier Gjerstorff
Journal:  Int J Mol Sci       Date:  2016-06-06       Impact factor: 5.923

10.  The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor.

Authors:  Mitchell S Stark; Lisa N Tom; Glen M Boyle; Vanessa F Bonazzi; H Peter Soyer; Adrian C Herington; Pamela M Pollock; Nicholas K Hayward
Journal:  Oncotarget       Date:  2016-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.